FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project

COMMENTED

Macular DiseasesRetinal Diseases

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ

doi: 10.1097/IAE.

COMMENTED

Macular DiseasesRetinal Diseases

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

Ophthalmology.

Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group

doi: 10.1016/j.ophtha.

Macular DiseasesRetinal Diseases

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Br J Ophthalmol.

Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group

doi: 10.1136/bjophthalmol-

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

Macular Diseases

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Ophthalmology.

Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, Hunt A, Gillies MC, Barthelmes D; Fight Retinal Blindness! Study Group

doi: 10.1016/j.ophtha.

Macular Diseases

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Ophthalmol Retina.

Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.

doi: 10.1016/j.oret.2019.06.001.

COMMENTED

Macular Diseases

Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project

Am J Ophthalmol.

Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M

doi: 10.1016/j.ajo.2019.03.001.

Macular Diseases

Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents

Ophthalmology.

Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J; Fight Retinal Blindness! Study Group

doi: 10.1016/j.ophtha.2018.11.036.

Macular Diseases

Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration

Ophthalmology.

Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC; Fight Retinal Blindness! Study Group

doi: 10.1016/

Related content

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project

Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents

Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration